B Masquelier
Overview
Explore the profile of B Masquelier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marcelin A, Visseaux B, Wirden M, Morand-Joubert L, Soulie C, Charpentier C, et al.
J Glob Antimicrob Resist
. 2016 Nov;
2(2):103-106.
PMID: 27873586
To treat human immunodeficiency virus (HIV)-infected patients, international guidelines recommend the combination of two nucleos(t)ide reverse transcriptase inhibitors [N(t)RTIs] and a third agent [non-NRTI (NNRTI), boosted protease inhibitor (r/PI) or...
2.
Noguera-Julian M, Cozzi-Lepri A, Di Giallonardo F, Schuurman R, Daumer M, Aitken S, et al.
Clin Microbiol Infect
. 2015 Oct;
22(2):191-200.
PMID: 26482266
Plasma drug-resistant minority human immunodeficiency virus type 1 variants (DRMVs) increase the risk of virological failure to first-line non-nucleoside reverse transcriptase inhibitor antiretroviral therapy (ART). The origin of DRMVs in...
3.
Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, et al.
J Antimicrob Chemother
. 2013 Dec;
69(4):1086-9.
PMID: 24302653
Objectives: In the context of simplification strategies, it is essential to know the feasibility of a switch to a rilpivirine-based therapy. The aim of this study was to describe rilpivirine,...
4.
Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, et al.
J Antimicrob Chemother
. 2013 Jan;
68(6):1237-42.
PMID: 23361642
Objectives: The prevalence of rilpivirine, emtricitabine and tenofovir resistance-associated mutations (RAMs), described in vitro and in vivo, was determined in antiretroviral-naive patients. Patients And Methods: From 2008 to 2011, 1729...
5.
Recordon-Pinson P, Raymond S, Bellecave P, Marcelin A, Soulie C, Descamps D, et al.
Antimicrob Agents Chemother
. 2012 Dec;
57(2):930-5.
PMID: 23208718
There is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants...
6.
Reigadas S, Marcelin A, Houssaini A, Yerly S, Descamps D, Plantier J, et al.
J Antimicrob Chemother
. 2012 Nov;
68(4):969-72.
PMID: 23184711
No abstract available.
7.
Reigadas S, Masquelier B, Calmels C, Laguerre M, Lazaro E, Vandenhende M, et al.
Antimicrob Agents Chemother
. 2011 May;
55(7):3187-94.
PMID: 21576445
The HIV-1 integrase (IN) mutations Y143C/R are known as raltegravir (RAL) primary resistance mutations. In a previous study (S. Reigadas et al., PLoS One 5:e10311, 2010), we investigated the genetic...
8.
Vandekerckhove L, Wensing A, Kaiser R, Brun-Vezinet F, Clotet B, De Luca A, et al.
Lancet Infect Dis
. 2011 Mar;
11(5):394-407.
PMID: 21429803
Viral tropism is the ability of viruses to enter and infect specific host cells and is based on the ability of viruses to bind to receptors on those cells. Testing...
9.
Masquelier B, Assoumou K, Descamps D, Bocket L, Cottalorda J, Ruffault A, et al.
J Antimicrob Chemother
. 2008 Apr;
61(6):1362-8.
PMID: 18390885
Background: We developed clinically relevant genotypic scores for resistance to fosamprenavir/ritonavir in HIV-1 protease inhibitor (PI)-experienced patients. Methods: PI-experienced patients with virological failure receiving fosamprenavir/ritonavir as the sole PI for...
10.
Dieval C, Bonnet F, Mauclere S, Masquelier B, Bentaberry F, Cazeau A, et al.
Leuk Lymphoma
. 2007 Sep;
48(9):1881-3.
PMID: 17786732
No abstract available.